Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Lancet Infect Dis. 2020 Dec 14;21(5):697–710. doi: 10.1016/S1473-3099(20)30523-5

Figure 3. Distribution of propensity scores (2:1 match) in the invasive group A β-haemolytic streptococcal infection cohort (A) and the invasive non-group A/B β-haemolytic streptococcal infection cohort (B).

Figure 3

Propensity scores were calculated from a logistic regression associated with receipt of clindamycin as a binary outcome to the matching variables (shown in the table) used as predictors for 1956 individuals. From the model, a fitted probability (propensity score) for each patient was calculated to estimate the likelihood of receiving adjunctive clindamycin based on their covariate profile of matching variable values. The propensity scores are visualised on the logit scale.